Research grant of £1.26M granted to QV Bioelectronics for furthering research on innovative brain cancer therapy
In the ongoing battle against brain cancer, a new treatment approach is showing promising results. QV Bioelectronics, a UK-based biotech company, is developing GRACE, an innovative Electric Field Therapy (EFT) device designed to treat brain tumors.
Current Status
GRACE is currently undergoing clinical trials to evaluate its safety and efficacy. Initial studies have focused on adult patients with glioblastoma or other malignant brain tumors. The device is being positioned for regulatory approvals, with the potential to join the ranks of other EFT devices like Novocure’s Optune, but with unique technical or application features.
Future Plans
QV Bioelectronics has ambitious plans for GRACE. The company aims to expand clinical testing to cover a broader patient population, including pediatric brain tumor patients and those with metastatic brain tumors. The potential to treat these often underserved patient groups represents a significant advancement in the field of neuro-oncology.
Moreover, there is potential to explore EFT in other solid tumors, based on the success of brain tumor applications. Additionally, efforts continue to optimize the portability, comfort, and usability of GRACE to improve patient compliance and quality of life during treatment.
A Promising Future
GRACE is the first fully implanted EFT system designed to deliver continuous, targeted therapy within the brain. If successful, it could significantly improve patient outcomes and quality of life for those with glioblastoma, a cancer with one of the poorest prognoses in oncology. The implant uses electric fields to disrupt cancer cell division while sparing healthy tissue.
QV Bioelectronics has reported encouraging preclinical safety and efficacy data, holds multiple granted patents, and has secured over 6 million GBP in grant funding and equity investment. The company's CEO, Dr Christopher Bullock, stated that a recent 1.26 million GBP grant under the Biomedical Catalyst programme represents a strong vote of confidence in their technology from the Innovate UK programme.
The University of Edinburgh is excited about the prospect of the first in human study for GRACE and has contributed to its development. If you want the most up-to-date details, especially about ongoing clinical trials or the latest regulatory milestones, following QV Bioelectronics’ official communications or clinical trial registries would be advisable.
In the realms of health-and-wellness and science, QV Bioelectronics is working diligently to expand clinical trials of GRACE, their innovative Electric Field Therapy (EFT) device, to include patients with various medical-conditions such as pediatric brain tumors and metastatic brain tumors, marking a significant progress in neuro-oncology. Leveraging the success of brain tumor applications, there's potential to explore EFT in treating other solid tumors and optimize the portability, comfort, and usability of GRACE for improved patient compliance and quality of life.
